Taxotere New Indication - Gastric Cancer Treatment Registration Trial

NCT ID: NCT00811447

Last Updated: 2012-08-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 243 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-11-30
• Study Completion Date: 2012-06-30

Brief Summary

Primary objective:

To detect a statistically significant increase in time to progression (TTP) of disease for the test group (Taxotere® [Docetaxel] combined with cisplatin and 5-fluorouracil [TCF]) relative to the control group (Cisplatin combined with 5-fluorouracil[CF])

Secondary objectives:

• To detect a statistically significant increase in overall survival (OS) for the test group relative to the control group.
• To compare response rate (RR), time to treatment failure (TTF), duration of responses, safety profiles, quality of life (QOL), and disease-related symptoms.

Conditions

Stomach Neoplasms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Administration of docetaxel 60 mg/m² on Day 1, Cisplatin 60 mg/m² after the end of the docetaxel infusion and 5-fluorouracil (5-FU) 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.

Group Type: EXPERIMENTAL

5-fluorouracil

Intervention Type: DRUG

600 mg/m²/day intravenous

Cisplatin

Intervention Type: DRUG

60 mg/m² or 75 mg/m² intravenous

Docetaxel

Intervention Type: DRUG

60 mg/m² intravenous

2

Cisplatin 75 mg/m² on Day 1, 5-FU 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.

Group Type: ACTIVE_COMPARATOR

5-fluorouracil

Intervention Type: DRUG

600 mg/m²/day intravenous

Cisplatin

Intervention Type: DRUG

60 mg/m² or 75 mg/m² intravenous

Interventions

5-fluorouracil

600 mg/m²/day intravenous

Intervention Type: DRUG

Cisplatin

60 mg/m² or 75 mg/m² intravenous

Intervention Type: DRUG

Docetaxel

60 mg/m² intravenous

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Gastric adenocarcinoma including adenocarcinoma of the esophagogastric junction, histologically proven.
• Measurable and/or evaluable metastatic disease; if a single metastatic lesion is the only manifestation of the disease, cytology or histology is mandatory. Locally recurrent disease is accepted provided that there is at least one measurable lesion.
• Performance status Karnofsky index >70%
• Life expectancy of more than 3 months
• Adequate haematological parameters (Hb≥9g/dl, ANC≥2.0× 109/L, platelets ≥ 100× 109/L)
• Creatinine ≤ 1.25 UNL, serum magnesium should be within the normal value
• Total bilirubin ≤ 1 UNL, AST and ALT ≤ 2.5 UNL, alkaline phosphatase ≤ 5 UNL
• No prior palliative chemotherapy, previous adjuvant chemotherapy is allowed if more than 12 months has elapsed between the end of adjuvant therapy and first relapse.
• At least 6 weeks from prior radiotherapy and 3 weeks from surgery
• Complete initial work-up within two weeks prior to first infusion for clinical evaluation and biological work-up. Abdominal CT scan and chest X-rays are mandatory.

Exclusion Criteria

• Pregnant or lactating women
• Patients with reproductive potential not implementing adequate contraceptive measures
• Other tumor type than adenocarcinoma
• Any prior palliative chemotherapy. Prior adjuvant chemotherapy with a first relapse within 12 months from the end of adjuvant
• Prior treatment with taxanes. Prior CDDP as adjuvant chemotherapy with cumulative dose > 300mg/m²
• Previous or current malignancies other than gastric carcinoma, with the exception of adequately treated in situ carcinoma of the cervix uteri or non melanoma skin cancer
• Patients with known brain or leptomeningeal metastases
• Symptomatic peripheral neuropathy ≥ grade 2 by NCIC-CTG criteria
• Other serious illness or medical conditions:

• unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry
• history of significant neurologic or psychiatric disorders including dementia or seizures
• active uncontrolled infection
• active disseminated intravascular coagulation
• other serious underlying medical conditions which could impair the ability of the patient to participate in the study
• Concurrent treatment with corticosteroids except as use for the prophylactic medication regimen, treatment of acute hypersensitivity reactions or unless chronic treatment at low doses
• Definite contraindications for the use of corticosteroids
• Hypercalcemia not controlled by bisphosphonates and more than 12mg/100ml
• Liver impairment with AST or ALT more than 1.5UNL associated with alkaline phosphatase more than 2.5UNL
• Concurrent or within 4 week period administration of any other experimental drugs
• Concurrent treatment with any other anti-cancer therapy

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Martin Thoenes

Role: STUDY_DIRECTOR

Sanofi

Locations

Sanofi-Aventis Administrative Office

Shanghai, , China

Countries

China

Other Identifiers

DOCET_L_02195

Identifier Type: -

Identifier Source: org_study_id